Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75996 | 0.91 | TRPV1 (0.53) | NAMPTPOLBF10TRPV1MAPT | |
| SCHEMBL85884 | 0.80 | LMNA (0.43) | LMNANPSR1POLBALOX15F10 | |
| SCHEMBL5075422 | 0.78 | F10 (0.56) | NAMPTF10TRPV1MAPTEPHX2 | |
| SCHEMBL75979 | 0.74 | TRPV1 (0.65) | NAMPTLMNAPOLBF10TRPV1 | |
| SCHEMBL29581288 | 0.72 | TSHR (0.51) | NAMPTPOLBF10MAPT | |
| SCHEMBL77565 | 0.72 | F10 (0.49) | POLBF10KMT2AMAPTEPHX2 | |
| SCHEMBL3833286 | 0.70 | F10 (0.66) | LMNAPOLBF10KDM4EKMT2A | |
| SCHEMBL8455933 | 0.69 | ALDH1A1 (0.60) | NAMPTLMNAF10KMT2A | |
| SCHEMBL8466843 | 0.69 | ALDH1A1 (0.60) | NAMPTLMNAF10KMT2A | |
| SCHEMBL27557817 | 0.69 | ITGB3 (0.51) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | NAMPT 3125/4885LMNA 918/4885NPSR1 2546/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | NAMPT 2823/4885LMNA 626/4885NPSR1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.